Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrizia Popoli

Showing results (11-20 of 92) with videos related to

Pageof 10
Sort By:
Global & Regional Health Technology Assessment|November 17, 2025
Patrizia Popoli, Walter Marrocco, Anna Ponzianelli, et al.
European Journal of Pharmacology|July 22, 2009
Region-specific neuroprotective effect of ZM 241385 towards glutamate uptake inhibition in cultured neuronsRita Pepponi, Antonella Ferrante, Roberta Ferretti, et al.
Thescientificworldjournal|September 16, 2010
Role of adenosine A(2A) receptors in modulating synaptic functions and brain levels of BDNF: a possible key mechanism in the pathophysiology of Huntington's diseaseMaria Teresa Tebano, Alberto Martire, Valentina Chiodi, et al.
Neurochemistry International|August 1, 2007
Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's diseaseTiziana Bisogno, Alberto Martire, Stefania Petrosino, et al.
Current Pharmaceutical Design|June 10, 2008
A critical evaluation of adenosine A2A receptors as potentially "druggable" targets in Huntington's diseasePatrizia Popoli, David Blum, Maria Rosaria Domenici, et al.
European Journal of Pharmacology|November 27, 2007
Behavioural and neurochemical characterization of the adenosine A2A receptor antagonist ST1535Mariangela Galluzzo, Anita Pintor, Antonella Pèzzola, et al.
The Lancet. Neurology|July 10, 2003
Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeuticsDavid Blum, Raphaël Hourez, Marie-Christine Galas, et al.
Progress in Neurobiology|February 17, 2007
Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's diseasePatrizia Popoli, David Blum, Alberto Martire, et al.
Journal of Neurochemistry|February 1, 2013
BDNF prevents NMDA-induced toxicity in models of Huntington's disease: the effects are genotype specific and adenosine A2A receptor is involvedAlberto Martire, Rita Pepponi, Maria Rosaria Domenici, et al.
Behavioural Brain Research|June 16, 2004
Progressive behavioural changes in the spatial open-field in the quinolinic acid rat model of Huntington's diseaseMaria Luisa Scattoni, Angelina Valanzano, Patrizia Popoli, et al.
Pageof 10

Showing results (11-20 of 92) with videos related to

Sort By:
Pageof 10
Global & Regional Health Technology Assessment|November 17, 2025
Patrizia Popoli, Walter Marrocco, Anna Ponzianelli, et al.
European Journal of Pharmacology|July 22, 2009
Region-specific neuroprotective effect of ZM 241385 towards glutamate uptake inhibition in cultured neuronsRita Pepponi, Antonella Ferrante, Roberta Ferretti, et al.
Thescientificworldjournal|September 16, 2010
Role of adenosine A(2A) receptors in modulating synaptic functions and brain levels of BDNF: a possible key mechanism in the pathophysiology of Huntington's diseaseMaria Teresa Tebano, Alberto Martire, Valentina Chiodi, et al.
Neurochemistry International|August 1, 2007
Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's diseaseTiziana Bisogno, Alberto Martire, Stefania Petrosino, et al.
Current Pharmaceutical Design|June 10, 2008
A critical evaluation of adenosine A2A receptors as potentially "druggable" targets in Huntington's diseasePatrizia Popoli, David Blum, Maria Rosaria Domenici, et al.
European Journal of Pharmacology|November 27, 2007
Behavioural and neurochemical characterization of the adenosine A2A receptor antagonist ST1535Mariangela Galluzzo, Anita Pintor, Antonella Pèzzola, et al.
The Lancet. Neurology|July 10, 2003
Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeuticsDavid Blum, Raphaël Hourez, Marie-Christine Galas, et al.
Progress in Neurobiology|February 17, 2007
Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's diseasePatrizia Popoli, David Blum, Alberto Martire, et al.
Journal of Neurochemistry|February 1, 2013
BDNF prevents NMDA-induced toxicity in models of Huntington's disease: the effects are genotype specific and adenosine A2A receptor is involvedAlberto Martire, Rita Pepponi, Maria Rosaria Domenici, et al.
Behavioural Brain Research|June 16, 2004
Progressive behavioural changes in the spatial open-field in the quinolinic acid rat model of Huntington's diseaseMaria Luisa Scattoni, Angelina Valanzano, Patrizia Popoli, et al.
Pageof 10